Skip to main content
    T

    Tvardi Therapeutics, Inc. (TVRD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.10
    -0.08 (-6.78%)

    Market Cap: $15.74M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Tvardi Therapeutics, Inc. (TVRD) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Tvardi Therapeutics (TVRD) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Tvardi Therapeutics reported EPS of -$0.48, above the -$0.51 estimate. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    24%(8/33)
    Avg Surprise
    +2.48%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.43
    Range-$0.83 - -$0.14
    11 analysts
    Revenue Consensus
    N/A
    RangeN/A
    9 analysts

    Next Report

    TVRD has an expected report date of Mar 29, 2027.

    Earnings History

    Of the 33 quarters below that had an estimate, TVRD beat 8, missed 10 and matched 15. The widest gap in the table came in the quarter ended Jun 30, 2025, when EPS landed 230.77% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.48-$0.51-$1.06 - -$0.28+5.88%BeatN/A82 up, 0 downNov 12, 2026N/A
    Jun 30, 2026-$0.69-$0.65-$0.78 - -$0.41-6.15%Miss-235.3%73 up, 1 downAug 13, 2026N/A
    Mar 31, 2026-$0.73-$0.65-$0.79 - -$0.51-12.31%MissN/A50 up, 2 downMay 8, 2026N/A
    Dec 31, 2025-$0.78-$0.57-$0.65 - -$0.50-36.84%MissN/A51 up, 0 downMar 31, 2026N/A
    Sep 30, 2025-$0.59-$0.81N/A+27.16%BeatN/A2N/ANov 13, 2025N/A
    Jun 30, 2025$0.51-$0.39N/A+230.77%BeatN/A2N/AAug 14, 2025N/A
    Mar 31, 2025-$0.50-$0.58N/A+13.79%BeatN/AN/AN/AMay 13, 2025N/A
    Dec 31, 2024-$5.21-$0.20N/AN/AN/AN/AN/AN/AFeb 26, 2025N/A
    Sep 30, 2024-$8.19-$8.64N/A+5.26%BeatN/AN/AN/ANov 29, 2024N/A
    Jun 30, 2024-$0.27-$0.26N/A-3.85%MissN/AN/AN/AAug 5, 2024N/A
    Mar 31, 2024-$0.56-$0.40N/A-40.00%MissN/AN/AN/AMay 13, 2024$2.13M
    Dec 31, 2023-$0.59-$0.45N/A-31.11%MissN/AN/AN/AMar 4, 2024$3.00M
    Sep 30, 2023-$0.52-$0.52N/A0.00%In lineN/AN/AN/ANov 13, 2023$4.87M
    Jun 30, 2023-$0.58-$0.54N/A-7.41%MissN/AN/AN/AAug 7, 2023$6.93M
    Mar 31, 2023-$0.49-$0.51N/A+3.92%BeatN/AN/AN/AMay 15, 2023$6.17M
    Dec 31, 2022-$0.56-$0.32N/A-75.00%MissN/AN/AN/AMar 6, 2023$3.26M
    Sep 30, 2022-$0.43-$0.43N/A0.00%In lineN/AN/AN/ANov 7, 2022$10.81M
    Jun 30, 2022-$0.08-$0.08N/A0.00%In lineN/AN/AN/AAug 8, 2022$23.00M
    Mar 31, 2022-$0.52-$0.52N/A0.00%In lineN/AN/AN/AMay 9, 2022$4.79M
    Dec 31, 2021-$0.63-$0.63N/A0.00%In line-139.6%N/AN/AMar 1, 2022$821000
    Sep 30, 2021-$0.02-$0.02N/A0.00%In lineN/AN/AN/ANov 8, 2021$20.27M
    Jun 30, 2021-$0.61-$0.61N/A0.00%In lineN/AN/AN/AAug 9, 2021N/A
    Mar 31, 2021-$0.47-$0.47N/A0.00%In lineN/AN/AN/AMay 10, 2021$1.94M
    Dec 31, 2020$1.59$1.59N/A0.00%In lineN/AN/AN/AFeb 25, 2021$102.82M
    Sep 30, 2020-$0.35-$0.35N/A0.00%In lineN/AN/AN/ANov 9, 2020$18.53M
    Jun 30, 2020-$0.54-$0.54N/A0.00%In lineN/AN/AN/AAug 10, 2020$5.63M
    Mar 31, 2020-$0.62-$0.62N/A0.00%In lineN/AN/AN/AMay 11, 2020$8.09M
    Dec 31, 2019-$0.61-$0.61N/A0.00%In lineN/AN/AN/AFeb 27, 2020$4.51M
    Sep 30, 2019-$0.74-$0.74N/A0.00%In lineN/AN/AN/ANov 5, 2019$5.79M
    Jun 30, 2019-$0.58-$0.58N/A0.00%In lineN/AN/AN/AAug 7, 2019$5.21M
    Mar 31, 2019-$0.56-$0.58N/A+3.45%BeatN/AN/AN/AMay 7, 2019$4.38M
    Dec 31, 2018-$0.52-$0.58N/A+10.34%BeatN/AN/AN/AMar 12, 2019$5.53M
    Sep 30, 2018-$0.51-$0.49N/A-4.08%MissN/AN/AN/ANov 6, 2018$5.06M
    Jun 30, 2018-$0.52-$0.51N/A-1.96%MissN/AN/AN/AAug 7, 2018$2.87M
    Mar 31, 2018-$18.47N/AN/AN/AN/AN/AN/AN/AMay 10, 2018N/A
    Dec 31, 2017-$15.64N/AN/AN/AN/AN/AN/AN/AMar 16, 2018N/A
    Sep 30, 2017-$13.75N/AN/AN/AN/AN/AN/AN/ANov 3, 2017N/A
    Jun 30, 2017-$10.38N/AN/AN/AN/AN/AN/AN/AAug 4, 2017N/A
    Mar 31, 2017-$29.28N/AN/AN/AN/AN/AN/AN/AMay 5, 2017$911000
    Dec 31, 2016-$28.98N/AN/AN/AN/AN/AN/AN/AMar 10, 2017N/A
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.36, after -$14.23 the year before. It was -$75.59 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.36N/A
    Dec 31, 2024-$14.23N/A
    Dec 31, 2023-$2.18N/A
    Dec 31, 2022-$1.59N/A
    Dec 31, 2021-$1.73-2262.5%
    Dec 31, 2020$0.08N/A
    Dec 31, 2019-$2.49N/A
    Dec 31, 2018-$20.02N/A
    Dec 31, 2017-$69.05N/A
    Dec 31, 2016-$75.59N/A

    Frequently Asked Questions About TVRD

    When is Tvardi Therapeutics's next earnings date?

    Tvardi Therapeutics's next earnings report is expected for Mar 29, 2027.

    Did TVRD beat earnings estimates last quarter?

    Yes. Tvardi Therapeutics reported EPS of -$0.48 for the quarter ended Sep 30, 2026, above the -$0.51 estimate, a 5.88% surprise.

    What EPS do analysts expect from TVRD next quarter?

    The consensus EPS estimate for Tvardi Therapeutics for the quarter ending Dec 31, 2026 is -$0.43 from 11 analysts, with estimates from -$0.83 to -$0.14.

    How often does TVRD beat earnings estimates?

    Tvardi Therapeutics beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of +28.45%.